1 |
Chemello L, Cavalletto L, Ferrari S, Monaco S. Impact of direct acting antivirals (DAA) on neurologic disorders in chronic hepatitis C. Minerva Gastroenterol (Torino) 2021;67:234-43. [PMID: 34672486 DOI: 10.23736/S2724-5985.21.02865-5] [Reference Citation Analysis]
|
2 |
Hanif FM, Majid Z, Luck NH, Tasneem AA, Laeeq SM, Mubarak M. Revolution in the diagnosis and management of hepatitis C virus infection in current era. World J Hepatol 2022; 14(4): 647-669 [DOI: 10.4254/wjh.v14.i4.647] [Reference Citation Analysis]
|
3 |
Wróblewska A, Bielawski KP, Sikorska K. Occult Infection with Hepatitis C Virus: Looking for Clear-Cut Boundaries and Methodological Consensus. JCM 2021;10:5874. [DOI: 10.3390/jcm10245874] [Reference Citation Analysis]
|
4 |
Torre P, Aglitti A, Masarone M, Persico M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J Gastroenterol 2021; 27(28): 4603-4638 [PMID: 34366625 DOI: 10.3748/wjg.v27.i28.4603] [Reference Citation Analysis]
|
5 |
Cohen-Bucay A, Francis JM, Gordon CE. Progress in hepatitis C virus management in chronic kidney disease. Curr Opin Nephrol Hypertens 2021;30:493-500. [PMID: 34054074 DOI: 10.1097/MNH.0000000000000729] [Reference Citation Analysis]
|
6 |
Cacoub P, Comarmond C, Vieira M, Régnier P, Saadoun D. HCV-related lymphoproliferative disorders in the direct-acting antiviral era: From mixed cryoglobulinaemia to B-cell lymphoma. J Hepatol 2021:S0168-8278(21)02084-5. [PMID: 34600000 DOI: 10.1016/j.jhep.2021.09.023] [Reference Citation Analysis]
|
7 |
Wang CR, Tsai HW. Human hepatitis viruses-associated cutaneous and systemic vasculitis. World J Gastroenterol 2021; 27(1): 19-36 [PMID: 33505148 DOI: 10.3748/wjg.v27.i1.19] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|